Sep 29, 2016
Bayer AG and Evotec AG enter a multi-target research partnership agreement Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement, Bayer will have all the rights to select clinical candidates and Evotec’s Cure Nephron target pipeline. It w...
Read More...
Sep 01, 2016
There has been a shocking revelation in a report published in Science Translational Medicine by Bengt Westermark, a tumour biologist at Uppsala, who reports that a cell line widely used to study brain cancer does not match the cells used to create the line nearly 50 years ago, or the tumour supposed to be its source...
Read More...
Jun 30, 2015
“We designed CAR T cells to overcome a number of problems in getting T cells to attack Cancer”-says Eshhar, after the development of first CAR-T cells (1989). CAR-T Technologies and History of Innovations Ever so often in the history of immunotherapy, there comes a breakthrough that takes cancer research ...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper